International Journal of Hematology This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Emicizumab-mediated hemostatic function assessed by thrombin generation assay in an in vitro model of factor VIII-depleted thrombophilia plasma
This study investigated the influence of natural anticoagulants on emicizumab-driven coagulation in HA model plasma. Various concentrations of PS and AT were added to PS-deficient plasma and AT-deficient plasma in the presence of anti-FVIII antibody (FVIIIAb; 10BU/mL). PC-deficient plasma was mixed with normal plasma at various concentrations in the presence of FVIIIAb. Emicizumab (50 µg/mL) was added to these thrombophilic HA model plasmas, prior to tissue factor/ellagic acid-triggered thrombin generation assays. Co-presence of emicizumab increased peak thrombin values (PeakTh) dependent on PS, AT, and PC concentrations....
Source: International Journal of Hematology - December 19, 2023 Category: Hematology Authors: Koji Yada Kenichi Ogiwara Naruto Shimonishi Yuto Nakajima Tetsuhiro Soeda Takehisa Kitazawa Keiji Nogami Source Type: research

Contribution of post-transplantation therapy to sustained MRD negativity in multiple myeloma: a retrospective analysis
In conclusion, post-transplantation therapy improved PFS and contributed to sustained MRD-negativity in myeloma patients.PMID:38103160 | DOI:10.1007/s12185-023-03682-z (Source: International Journal of Hematology)
Source: International Journal of Hematology - December 16, 2023 Category: Hematology Authors: Kazuhito Suzuki Tadahiro Gunji Masaharu Kawashima Hideki Uryu Riku Nagao Mamiko Momoki Hiroki Yokoyama Hiroto Ishii Susumu Tanoue Takeshi Saito Kaichi Nishiwaki Shingo Yano Source Type: research

Association of physical activity with bleeding events and safety in patients with haemophilia A starting emicizumab prophylaxis: an interim analysis of the TSUBASA study
CONCLUSIONS: PwHA receiving emicizumab in the TSUBASA study experienced minimal bleeding associated with physical activity.TRIAL REGISTRATION: Trial registration: UMIN-CTR ID: UMIN000037448.PMID:38100026 | DOI:10.1007/s12185-023-03679-8 (Source: International Journal of Hematology)
Source: International Journal of Hematology - December 15, 2023 Category: Hematology Authors: Keiji Nogami Teruhisa Fujii Akihiro Sawada Azusa Nagao Chiai Nagae Masanori Nojima Nobuaki Suzuki Daisuke Nosaka Tomomi Shimura Yoshimasa Sugao Kagehiro Amano Source Type: research

Real-world data of MDS and CMML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11)
Int J Hematol. 2023 Dec 13. doi: 10.1007/s12185-023-03686-9. Online ahead of print.ABSTRACTWe conducted a multicenter, prospective observational study of acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and chronic myelomonocytic leukemia (CMML) in Japan. From August 2011 to January 2016, we enrolled 6568 patients. Herein, we report the results for MDS (n = 2747) and CMML (n = 182). The percentage of patients aged 65 years or older was 79.5% for MDS and 79.7% for CMML. The estimated overall survival (OS) rate and cumulative incidence of AML evolution at 5 years were 32.3% (95% confidence interval: 30.2-34.5%)...
Source: International Journal of Hematology - December 13, 2023 Category: Hematology Authors: Kensuke Usuki Shigeki Ohtake Sumihisa Honda Mitsuhiro Matsuda Atsushi Wakita Yuichiro Nawa Ken Takase Akio Maeda Nobuo Sezaki Hisayuki Yokoyama Satoru Takada Daiki Hirano Tatsuki Tomikawa Masahiko Sumi Shingo Yano Hiroshi Handa Shuichi Ota Hiroyuki Fujita Source Type: research

Clinical significance of total nucleated cell count in bone marrow of patients with acute lymphoblastic leukemia who underwent allogeneic hematopoietic stem cell transplantation
Int J Hematol. 2023 Dec 12. doi: 10.1007/s12185-023-03688-7. Online ahead of print.ABSTRACTThe clinical implications of recipient bone marrow nucleated cell count (NCC) prior to allogeneic hematopoietic stem cell transplantation (allo-HSCT) remain unknown. We conducted a multicenter retrospective study to evaluate the clinical significance of bone marrow NCC prior to allo-HSCT in patients with acute lymphoblastic leukemia. Patients who were in remission and underwent the initial allo-HSCT were included and stratified into high- and low-NCC groups using an NCC of 10 × 104/µL as the cut-off. The 3-year overall survival (OS...
Source: International Journal of Hematology - December 11, 2023 Category: Hematology Authors: Jun Nukui Takayoshi Tachibana Takuya Miyazaki Masatsugu Tanaka Kenji Matsumoto Yoshimi Ishii Ayumi Numata Yuki Nakajima Ayako Matsumura Taisei Suzuki Akihiko Izumi Natsuki Hirose Koji Yamamoto Maki Hagihara Shin Fujisawa Heiwa Kanamori Hideaki Nakajima Source Type: research

Negative impact of immunoparesis in response to anti-SARS-CoV-2 mRNA vaccination of patients with multiple myeloma
This study analyzed the humoral response to the anti-SARS-CoV-2 messenger ribonucleic acid (mRNA) vaccine and its associated factor in 83 patients from June to November 2021 at seven member institutions of the Kyoto Clinical Hematology Study Group. SARS-CoV-2 neutralizing antibody (nAb) was measured from 12 to 210 days. The result revealed that 40 (48.2%) patients with MM and 59 (100%) healthy controls became seropositive after vaccination. Receiver operating characteristic curve analysis identified serum immunoglobulin (Ig) M of > 18 mg/dL at vaccination as the optimal threshold level associated with seropositivity in ...
Source: International Journal of Hematology - December 11, 2023 Category: Hematology Authors: Akio Onishi Yayoi Matsumura-Kimoto Shinsuke Mizutani Reiko Isa Takahiro Fujino Taku Tsukamoto Akihiro Miyashita Keita Okumura Daichi Nishiyama Koichi Hirakawa Kazuho Shimura Hiroto Kaneko Miki Kiyota Eri Kawata Ryoichi Takahashi Tsutomu Kobayashi Hitoji U Source Type: research

Real-world data of AML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11)
This report covers acute myeloid leukemia (AML) results from a multicenter, prospective observational study of AML, myelodysplastic syndromes, and chronic myelomonocytic leukemia in Japan. From August 2011 to January 2016, 3728 AML patients were registered. Among them, 42% were younger than 65, and the male-to-female ratio was 1.57:1. With a median follow-up time of 1807 days (95% confidence interval [CI]: 1732-1844 days), the estimated 5-year overall survival (OS) rate in AML patients (n = 3707) was 31.1% (95% CI: 29.5-32.8%). Trial-enrolled patients had a 1.7-fold higher OS rate than non-enrolled patients (5-year OS, 58....
Source: International Journal of Hematology - November 28, 2023 Category: Hematology Authors: Kensuke Usuki Shigeki Ohtake Sumihisa Honda Mitsuhiro Matsuda Atsushi Wakita Yuichiro Nawa Ken Takase Akio Maeda Nobuo Sezaki Hisayuki Yokoyama Satoru Takada Daiki Hirano Tatsuki Tomikawa Masahiko Sumi Shingo Yano Hiroshi Handa Shuichi Ota Hiroyuki Fujita Source Type: research